Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes

被引：0

作者：

Reinisch, Mattea ^{[1
]}

Harbeck, Nadia ^{[2
]}

Rastogi, Priya ^{[3
,4
]}

O'shaughnessy, Joyce ^{[5
]}

Boyle, Frances ^{[6
]}

Cortes, Javier ^{[7
,8
]}

Rugo, Hope S. ^{[9
]}

Hamilton, Erika ^{[10
]}

Goetz, Matthew P. ^{[11
]}

Huang, Chiun-Sheng ^{[12
]}

Senkus, Elzbieta ^{[13
]}

Trakin, Alexey ^{[14
]}

Neven, Patrick ^{[15
]}

Huober, Jens ^{[16
]}

Ran, Wei ^{[17
]}

Andre, Valerie ^{[17
]}

Munoz-Fernandez, Maria ^{[17
]}

Antonio, Belen San ^{[17
]}

Shahir, Ashwin ^{[17
]}

Martin, Miguel ^{[18
]}

Johnston, Stephen ^{[19
]}

机构：

[1] Evang Kliniken Essen Mitte, Clin Gynecol, Breast Ctr, Essen, Germany

[2] LMU Univ Hosp, Comprehens Canc Ctr Munchen, Dept Gynecol & Obstet, Breast Ctr, Munich, Germany

[3] UPMC, Hillman Canc Ctr, Pittsburgh, PA USA

[4] NSABP Fdn, Pittsburgh, PA USA

[5] Baylor Univ, Texas Oncol, US Oncol, Med Ctr, Dallas, TX USA

[6] Univ Sydney, Sydney Med Sch 4, Sydney, NSW, Australia

[7] Quironsalud Grp, Int Breast Canc Ctr IBCC 5, Barcelona, Spain

[8] Int Breast Canc Ctr IBCC, Quironsalud Grp, Barcelona, Spain

[9] Univ Calif San Francisco, Dept Med, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[10] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA

[11] Mayo Clin, Rochester, MN USA

[12] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Surg, Coll Med, Taipei, Taiwan

[13] Med Univ Gdansk, Gdansk, Poland

[14] NN Blokhin Russian Canc Res Ctr, Moscow, Russia

[15] Univ Hosp Leuven, Multidisciplinary Breast Ctr, Louvain, Belgium

[16] Kantonsspital St Gallen, Breast Ctr, St Gallen, Switzerland

[17] Eli Lilly & Co, Indianapolis, IN USA

[18] Univ Complutense Madrid, Hosp Gen Univ Gregorio Maranon, CIBERONC, GEICAM, Madrid, Spain

[19] Royal Marsden NHS Fdn Trust, London, England

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2024年 / 47卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1085

引用

页码：227 / 228

页数：2

共 50 条

[1] Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes
Harbeck, N.
Rastogi, P.
O'Shaughnessy, J.
Boyle, F.
Cortes, J.
Rugo, H. S.
Goetz, M. P.
Hamilton, E. P.
Huang, C.
Senkus-Konefka, E.
Tryakin, A.
Neven, P.
Huober, J.
Wei, R. J.
Andre, V.
Munoz, M.
Antonio, B. San
Shahir, A.
Jimenez, M. Martin
Johnston, S. R. D.
ANNALS OF ONCOLOGY, 2023, 34 : S1256 - S1256
[2] Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2-, High-risk Early Breast cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-year Efficacy Outcomes
Andre, V.
Harbeck, N.
Rastogi, P.
O'Shaughnessy, J.
Boyle, F.
Cortes, J.
Rugo, H. S.
Goetz, M. P.
Hamilton, E.
Huang, C. -s.
Senkus, E.
Tryakin, A.
Neven, P.
Huober, J.
Wei, R.
Munoz, M.
Antonio, B. S.
Shahir, A.
Martin, M.
Johnston, S.
BREAST, 2025, 80
[3] Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes
Johnston, Stephen
Toi, Masakazu
O'Shaughnessy, Joyce
Rastogi, Priya
Campone, Mario
Neven, Patrick
Huang, Chiun Sheng
Huober, Jens
Jaliffe, Georgina Garnica
Cicin, Irfan
Tolaney, Sara
Goetz, Matthew P.
Rugo, Hope
Senkus, Elzbieta
Testa, Laura
Del Mastro, Lucia
Shimizu, Chikako
Wei, Ran
Shahir, Ashwin
Munoz, Maria
Antonio, Belen San
Andre, Valerie
Harbeck, Nadia
Martin, Miguel
CANCER RESEARCH, 2023, 83 (05)
[4] Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
Rastogi, Priya
O'Shaughnessy, Joyce
Martin, Miguel
Boyle, Frances
Cortes, Javier
Rugo, Hope S.
Goetz, Matthew P.
Hamilton, Erika P.
Huang, Chiun-Sheng
Senkus, Elzbieta
Tryakin, Alexey
Cicin, Irfan
Testa, Laura
Neven, Patrick
Huober, Jens
Shao, Zhimin
Wei, Ran
Andre, Valerie
Munoz, Maria
San Antonio, Belen
Shahir, Ashwin
Harbeck, Nadia
Johnston, Stephen
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (09) : 987 - 993
[5] Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Johnston, Stephen R. D.
Harbeck, Nadia
Hegg, Roberto
Toi, Masakazu
Martin, Miguel
Shao, Zhi Min
Zhang, Qing Yuan
Martinez Rodriguez, Jorge Luis
Campone, Mario
Hamilton, Erika
Sohn, Joohyuk
Guarneri, Valentina
Okada, Morihito
Boyle, Frances
Neven, Patrick
Cortes, Javier
Huober, Jens
Wardley, Andrew
Tolaney, Sara M.
Cicin, Irfan
Smith, Ian C.
Frenzel, Martin
Headley, Desiree
Wei, Ran
San Antonio, Belen
Hulstijn, Maarten
Cox, Joanne
O'Shaughnessy, Joyce
Rastogi, Priya
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34) : 3987 - 3998
[6] Abemaciclib plus endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes
Johnston, S.
Toi, M.
O'Shaughnessy, J.
Rastogi, P.
Campone, M.
Neven, P.
Huang, C. S.
Huober, J.
Jaliffe, G. Garnica
Cicin, I.
Tolaney, S.
Goetz, M. P.
Rugo, H.
Senkus, E.
Testa, L.
Del Mastro, L.
Shimizu, C.
Wei, R.
Shahir, A.
Munoz, M.
Antonio, B. San
Andre, V.
Harbeck, N.
Martin, M.
BREAST, 2023, 68 : S22 - S23
[7] Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer
Paluch-Shimon, Shani
Neven, Patrick
Huober, Jens
Cicin, Irfan
Goetz, Matthew P. P.
Shimizu, Chikako
Huang, Chiun-Sheng
Lueck, Hans Joachim
Beith, Jane
Tokunaga, Eriko
Contreras, Jessica Reyes
de Sant'Ana, Rosane Oliveira
Wei, Ran
Shahir, Ashwin
Nabinger, Sarah C. C.
Forrester, Tammy
Johnston, Stephen R. D.
Harbeck, Nadia
monarchE Investigators
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[8] Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer
Tolaney, Sara M.
Guarneri, Valentina
Seo, Jae Hong
Cruz, Josefina
Abreu, Miguel Henriques
Takahashi, Masato
Barrios, Carlos
McIntyre, Kristi
Wei, Ran
Munoz, Maria
San Antonio, Belen
Liepa, Astra M.
Martin, Miguel
Johnston, Stephen R. D.
Kellokumpu-Lehtinen, Pirkko-Liisa
Harbeck, Nadia
EUROPEAN JOURNAL OF CANCER, 2024, 199
[9] Long-term Patient-reported Outcomes from monarchE: Abemaciclib plus Endocrine Therapy for Adjuvant HR+, HER2-, Node-positive, High-risk, Early Breast Cancer
Harbeck, Nadia
Guarneri, Valentina
Seo, Jae Hong
Cruz, Josefina
Abreu, Miguel Henriques
Takahashi, Masato
Barrios, Carlos
Mcintyre, Kristi
Wei, Ran
Antonio, Belen San
Liepa, Astra M.
Martin, Miguel
Johnston, Stephen R. D.
Tolaney, Sara M.
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 31 - 31
[10] Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
Hamilton, Erika P.
Kim, Jee Hyun
Eigeliene, Natalja
Mavroudis, Dimitrios
Median, Dragos Mircea
Marconato, Heloisa
Shevnia, Serhii
Ozyilkan, Ozgur
Puig, Juan Manuel
Shannon, Catherine M.
Munoz, Maria
San Antonio, Belen
Wei, Ran
O'Shaughnessy, Joyce
Johnston, Stephen R. D.
Guarneri, Valentina
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →